Cervavac: First indigenously developed Human Papillomavirus Vaccine

On 1^st September, 2022, the government announced the scientific completion of Cervavac, India’s first indigenously developed quadrivalent human papillomavirus (qHPV) vaccine for the prevention of cervical cancer.

About Cervavac: Cervavac is developed by the Pune-based Serum Institute of India in coordination with the Government of India’s Department of Biotechnology (DBT).

Effectiveness: HPV vaccines are given in two doses and data has shown that the antibodies that develop after both are administered can last up to six or seven years.

• The HPV vaccine protects the body against the human papillomavirus (HPV), which can cause vaginal, vulvar, anal and oral cancers, besides cervical cancer.

Do You Want to Read More?Login/Register Related Content 1 Global Research on Antimicrobial Resistance Report 2 Cervavac: First indigenously developed Human Papillomavirus Vaccine 3 Cabotegravir and Rilpivirine 4 C-CAMP Launches India AMR Innovation Hub 5 New Gene Therapy for Cancer Treatment 6 Brain-eating Amoeba 7 Immune Imprinting Successful Ooops! OK Try Other Content Log Out × Are you sure you want to log-off? Cancel